Nuo Therapeutics, Inc. (AURX)
OQB · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Nuo Therapeutics, Inc.
Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. Its customers include hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was incorporated in 1998 and is based in Houston, Texas.
Quarterly Financials
| Metric | 2025-03-31 | 2025-06-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 484K | 700K | 1.1M | 1.3M |
| Gross Profit | 363K | 541K | 688K | 850K |
| Operating Income | -745K | -652K | -579K | -446K |
| Net Income | -746K | -650K | -578K | -618K |
| Diluted EPS | $-0.02 | $-0.01 | $nan | $-0.01 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 112K | 609K | 1.4M | 3.3M |
| Gross Profit | 93K | 482K | 1.1M | 2.2M |
| Operating Income | -3.3M | -3.2M | -2.5M | -2.5M |
| Net Income | -3.2M | -3.2M | -2.3M | -2.5M |
| Diluted EPS | $-0.08 | $-0.08 | $-0.05 | $-0.05 |